Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 122-128

  Ogasawara, Akihito ^a   Utoh, Masahiro ^b   Nii, Kazuo ^b   Ueda, Ayumi ^b   Yoshikawa, Takahiro ^b   Kume, Toshiyuki ^a   Fukuzaki, Koichiro ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CYTOCHROME P450 3A; KETOCONAZOLE; SIMVASTATIN; SIMVASTATIN ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER METABOLISM; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFUSIONS, INTRAVENOUS; KETOCONAZOLE; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; SIMVASTATIN;

ANIMALIA; MACACA FASCICULARIS;

EID: 58149460403     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022574     Document Type: Article

References (34)

1. Chung E, Nafziger AN, Kazierad DJ, and Bertino JS Jr (2006) Comparison of midazolam and simvastatin as cytoclirome P450 3A probes. Clin Pharmacol Ther 79:350-361.
2. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
3. Duggan D and Vickers S (1990) Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab Rev 22:333-362.
4. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressier D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
5. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175.
6. Galetin A, Hinton LK, Burt H, Obach RS, and Houston JB (2007) Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693.
7. Gilad R and Lampl Y (1999) Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 22:295-297.
8. Gomez DY, Wacher VJ, Tomlanovich SJ Hebert MF, and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavai lability of cvclosporine. Clin Pharmacol Ther 58:15-19.
9. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, and Tobert JA (1999) Concomitant use of cytoclirome P450 3A4 inhibitors and simvastatin. Am J Cardiol 84:811-815.
10. Hashizume T, Mise M, Matsumoto S, Terauchi Y, Fujii T, Imaoka S, Funae Y, Kamataki T, and Miyazaki H (2001) A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 29:798-805.
11. Ishigami M, Kawabata K, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab Dispos 29:1068-1072.
12. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
13. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alternations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
14. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drng metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
15. Kanazu T, Yamaguchi Y, Okamura N, Baba T, and Koike M (2004) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391-402.
16. Khaliq Y, Gallicano K, Venance S, Kravcik S, and Cameron DW (2000) Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 68:637-646.
17. Komori M, Kikuchi O, Sakuma T, Funaki J, Kitada M, and Kamataki T (1992) Molecular cloning of monkey liver cytoclirome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450. Biochim Biophys Acta 1171:141-146.
18. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, and Greenblatt DJ (2002) In vivo, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228-1237.
19. Lilja JJ, Kivistö KT, and Neuvonen PJ (1998) Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477-483.
20. Masica AL, Mayo G, and Wilkinson GR (2004) In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76:341-349.
21. Neuvonen PJ, Kantola T, and Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
22. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
23. Ogasawara A, Kume T, and Kazama E (2007) Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cvnomolgus monkevs. Drug Metab Dispos 35:410-418.
24. Ohba M, Ohnishi N, Komada F, Iwakawa S, and Okumura K (1996) Effect of clarithromycin on the bioavailability of cyclosporine in rats. Biol Pharm Bull 19:733-737.
25. Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, and Yamazaki H (1997) Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401-408.
26. Tahara H, Kusuhara H, Chida M, Fuse E, and Sugiyama Y (2006) Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Phannacol Exp Ther 316:1187-1194.
27. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
28. Tsuruta S, Nakamura K, Arimori K, and Nakano M (1997) Effects of erythromycin, clarithromycin and rokitamycin on nifedipine metabolism in rats. Biol Pharm Bull 20:411-416.
29. Vickers S, Duncan CA, Chen IW, Rosegay A, and Duggan DE (1990) Metabolic dispositions on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18:138-145.
30. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
31. Ward KW, Proksch JW, Levy MA, and Smith BR (2001) Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics. Drug Metab Dispos 29:82-88.
32. Ward KW and Smith BR (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. L Clearance. Drug Metab Dispos 32:603-611.
33. Williams D and Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343-370.
34. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism. Drug Metab Dispos 29:443-452.